



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re patent application of Hotez et al.

Serial number: 10/825,692

Group Art Unit: 1645

Attorney Docket Number: 03740007aa

Examiner: Zeman

Filed: 2003-07-16

For: ***"HOOKWORM VACCINE"***

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING AND STATEMENT TO SUPPORT
FILING IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed 04/14/2006, we enclose herein a corrected substitute computer readable form (diskette) and a corrected substitute paper copy of the sequence listings for the above-identified patent application. Also enclosed is a verified statement that the content of the paper and computer readable copies are the same and include no new matter.

Respectfully submitted,

Ruth E. Tyler-Cross
Registration No. 45,922

Whitham, Curtis, Christofferson & Cook
11491 Sunset Hills Road; Suite 340
Reston, VA 20190
703-787-9400



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of Hotez et al.

Serial number: 10/825,692

Attorney Docket Number: 03740007aa

Filed: 2004-04-16

For: **"HOOKWORM VACCINE"**

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH
37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Mail Stop SEQUENCE


Dear Sir:

In connection with a Substitute Sequence Listing submitted concurrently herewith, the undersigned states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821 (g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that

such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Ruth E. Tyler-Cross', written over a horizontal line.

Ruth E. Tyler-Cross

Reg. No. 45,922

04/19/2006

Date

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a ASequence Listing as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up Raw Sequence Listing.
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the Sequence Listing is not the same as the computer readable from of the ASequence Listing as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: the specification contains sequences without the required sequence identifiers (see pages 87, 105 and 123 for example).

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the Sequence Listing..
- ☒ An initial or substitute paper copy of the Sequence Listing, as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY